Amman, Jordan - Hikma Pharmaceuticals has announced the initiation of a partnership agreement with Ergomed, an international provider of drug development services headquartered in Germany. The agreement will see Ergomed manage clinical trials of Hikma treatments in a pilot project in Jordan.
The agreement was signed in September 2011, and a meeting between the CEO and CFO of Ergomed and Hikma's CEO and management team was held on Wednesday January 18. Ergomed will be conducting the first clinical trials for one of Hikma's key oncology (anti-cancer) products in Jordanian hospitals with plans of potential expansion in the MENA region.. In turn, Hikma will provide Ergomed with an expanded insight into the regional pharmaceutical sector.
Mr. Said Darwazah, CEO of Hikma Pharmaceuticals, stated, "We are very pleased to announce the commencement of our partnership with Ergomed. They have a well-deserved reputation for excellence in the pharmaceutical sector and they will enhance Hikma's ability to provide the best treatments for patients in Jordan and across the MENA region. As organisations, Hikma and Ergomed complement each other well, with great potential for operational synergies."
"Our decision to work with Ergomed comes from a strong commitment to continuous medical advancement through the use of clinical trials, especially in the field of oncology. We are the leading company in our sector, and we want to continue providing the optimum treatments to our patients. Collaborating with Ergomed will ensure that we do so."
Dr. Miroslav Reljanovic, CEO of Ergomed, stated, "We are very pleased to be working with Hikma on these initiatives. Ergomed has over thirteen years experience of international drug development and is currently developing a full service MENA business managed from its Dubai head office.
We share Hikma's proven commitment to quality and to meeting the needs of doctors and patients and we look forward to working on this and future projects"
-Ends-
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East; North Africa ("MENA") region, where it is a market leader; the United States; and Europe.
For news and other information, please visit www.hikma.com .
FTI Consulting
Name: Manash Bhuyan
Email: manash.bhuyan@fticonsulting.com
Tel: (971) 4 332 8832
Fax:(+971) 4 332 8388
HIKMA Pharmaceuticals
Name: Hana Ramadan, Hala Khayyat
Email: ramadanh@Hikma.com , hkhayyat@Hikma.com
Tel: Hana Ramadan (+962) 6 5802900 Ext. 313
Tel: Hala Khayyat (+962) 6 5802900 Ext. 311
About ERGOMED
ERGOMED is a specialised international clinical development company offering contract clinical research and co-development partnerships to biotechnology and pharmaceutical companies worldwide in the fields of neurology, oncology and immunology. ERGOMED's approach to clinical research ensures effective patient recruitment, reducing the time and costs of clinical trials and complementing the drug discovery capabilities of its customers and partners. The Company has a dual business model offering standard clinical trial management contracts and also co-development partnerships to share the risks and rewards of clinical development.
ERGOMED is headquartered in Frankfurt, Germany and also has offices in UK, Russia, Croatia, Poland, Spain, Serbia, Italy and the USA. ERGOMED MENA is an integrated part of the group and is currently working for a range of local and international clients in the region.
For further information visit www.ergomed-cro.com or alternatively please contact:
ERGOMED Group:
Dr Miroslav Reljanovic, CEO
t: +385 (0) 1 4628 503
e-mail: ergomed@ergomed-cro.com
Neil Clark, CFO & COO
t: +44 (0) 1223 370 111
e-mail: neil.clark@ergomed-cro.com
Press Release 2012
